Loading...
Loading...
Viking Therapeutics Inc VKTX released 52-week histologic data from its Phase 2b VOYAGE study of VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH) . As previously reported, the study achieved its primary endpoint, with patients receiving VK2809 experiencing statistically significant reductions in liver fat content from baseline to Week 12 compared to placebo . The results announced highlight the achievement of secondary endpoints evaluating histologic changes assessed by hepatic biopsy after 52 weeks of treatment with VK2809.
Also Read: Viking Therapeutics’ Weight Loss Study Data Outperformed Novo Nordisk, Eli Lilly Studies, Analysts Say . On the secondary endpoint of NASH resolution with no worsening of fibrosis, VK2809-treated patients demonstrated NASH resolution ranging from 63% to 75%, compared with 29% for placebo. Across the combined VK2809 treatment groups, 69% achieved NASH resolution.
On the secondary endpoint evaluating improvement in fibrosis with no worsening of NASH, VK2809-treated patients demonstrated improvement in fibrosis ranging from 44% to 57%, compared with 34% for placebo. Across the combined VK2809 treatment groups, 51% achieved improvement in fibrosis with no worsening of NASH. On the secondary endpoint evaluating the proportion of patients experiencing both resolution of NASH and improvement in fibrosis, VK2809-treated patients demonstrated improvement between 40% to 50%, compared with 20% for placeb.
